{
    "clinical_study": {
        "@rank": "126043", 
        "arm_group": [
            {
                "arm_group_label": "YH12852", 
                "arm_group_type": "Experimental", 
                "description": "Experimental:   YH12852\nExperimental: YH12852 1mg\nsingle dose, qd\nExperimental: YH12852 3mg\nsingle dose, qd\nExperimental: YH12852 10mg\nsingle dose, qd\nExperimental: YH12852 20mg\nsingle dose, qd\nExperimental: YH12852 40mg\nsingle dose, qd\nExperimental: YH12852 60mg\nsingle dose, qd\nExperimental: YH12852 1mg\nrepeat dose, qd\nExperimental: YH12852 3mg\nrepeat dose, qd\nExperimental: YH12852 10mg\nrepeat dose, qd\nExperimental: YH12852 20mg\nrepeat dose, qd\nEach experimetal contains 12 subjects. 12 subjects were administered YH12852 x mg or active/placebo comparators.(YH12852:active:placebo=8:2:2) Additional 1 period would be processed in SAD YH12852 20mg group for observing food effect and in MAD YH12852 10mg group for bid administration"
            }, 
            {
                "arm_group_label": "Prucalopride", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Study to evaluate the safety/tolerability and pharmacokinetics/pharmacodynamics(PK/PD)of\n      YH12852 after oral administration in healthy male subjects"
        }, 
        "brief_title": "Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH12852 After Oral Administration in Healthy Male Subjects", 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  healty male aged 20 to 45 with body mass index(BMI) between 18 and 25kg/m2\n\n          -  Subject who has no congential, chronic disease and disease symptoms in medical\n             examination result\n\n          -  Subject who is judged to be eligible by porincipal inverstigator or sub-investigator\n             according to various reasons includiong ther abnorminal test results(clinical\n             laboratory test, 12-lead ECG etc)\n\n          -  Subjects who has signed a written informed consent voluntarily,prior to any\n             porcedure, using a form that is approved by the local Institutional Review Board\n             after detail explanation of the purpose, contents, and characteristic of the drug\n\n        Exclusion Criteria:\n\n          -  Suject who has history or presence of clinically significant diseases in liver,\n             kidney, gastrointestinal tract, nervous system, respiratory system, endocrine system,\n             blood tumor, cardiovascular, urinary system, and mental disorder\n\n          -  Subject who is hypersensitive to components contained in YH12852 or prucalopride or\n             aspirin/antibiotics like drugs\n\n          -  Medical history of gastrointestinal disease or acid restraining surgery, gastric/\n             eshophagus surgery(excluding appendectomy, hernia surgery)\n\n          -  Clinically significant abnormal values in dignostic check within 28 days before the\n             treatment(>1.25 fold of normal upper limit in the levels of AST or ALT, >1.5 fold of\n             normal upper limit in the levels of Total bilirubin, < 80ml/min of Cockcroft-Gault\n             used creatinine clearance\n\n          -  Subject has over QTc interval of 550 ms or PR interval of 210 ms or QRS interval of\n             120 ms or QT interval of 500 ms on baseline 12-lead ECG, as determined by the\n             Investigator\n\n          -  Subject who had taken usual dose of any prescription durgs within 14 days before the\n             treatment  or who had used usual dose of OTC drugs within 7 days before the treatment\n\n          -  Subject who participated in antoher clinical trail within 2 monthes before enrolling\n             in this study\n\n          -  subject who donated whole blood within 2 months or component blood within 1 month\n             before the treatment\n\n          -  Medically unacceptable contraception used during the clinical trial\n\n          -  Subject who drank over 30g/day or were detected alcohol positive on test\n\n          -  Subject sho stopped smoking within 3 months before the treatment or weren't able to\n             stop smoking during the hospitalization\n\n          -  Subject who had a beverage containing caffeine during the hospitalization\n\n          -  Subjects with clinically significant observations considered as unsuitable based on\n             medical judgment by investigators"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01870674", 
            "org_study_id": "YH12852-101"
        }, 
        "intervention": [
            {
                "arm_group_label": "YH12852", 
                "description": "there are 6 SAD group and 4 MAD group. In each group, 8 subjects take YH12852.", 
                "intervention_name": "YH12852", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Prucalopride", 
                "description": "There are 6 SAD group and 4 MAD group. In each group, 2 subjects take prucalopride.", 
                "intervention_name": "Prucalopride", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "There are 6 SAD group and 4 MAD group. In each group, 2 subjects take placebo.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "safety/tolerability and pharmacokinetics/pharmacodynamics", 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Busan", 
                    "country": "Korea, Republic of", 
                    "zip": "614-735"
                }, 
                "name": "Inje Busan Paik hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-blind, Placebo/Active-controlled, Single/Multiple Dose Ascending Phase 1 Clinical Study to Investigate the Safety/Tolerability and PK/PD of YH12852 After Oral Administration in Healthy Male Subjects", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "the number of adverse event, seriousness of adverse event", 
                "safety_issue": "Yes", 
                "time_frame": "blood and urine sampling during 0-48hr on SAD cohort, blood sampling during day 1, day 12-15 and urine sampling during day 1-2, day 14-15 on MAD cohort"
            }, 
            {
                "measure": "significant changes in vital sign", 
                "safety_issue": "Yes", 
                "time_frame": "blood and urine sampling during 0-48hr on SAD cohort, blood sampling during day 1, day 12-15 and urine sampling during day 1-2, day 14-15 on MAD cohort"
            }, 
            {
                "measure": "significant changes in 12-lead electrocardiography", 
                "safety_issue": "Yes", 
                "time_frame": "blood and urine sampling during 0-48hr on SAD cohort, blood sampling during day 1, day 12-15 and urine sampling during day 1-2, day 14-15 on MAD cohort"
            }, 
            {
                "measure": "significantchanges in laboratory test", 
                "safety_issue": "Yes", 
                "time_frame": "blood and urine sampling during 0-48hr on SAD cohort, blood sampling during day 1, day 12-15 and urine sampling during day 1-2, day 14-15 on MAD cohort"
            }, 
            {
                "measure": "significant physical exam", 
                "safety_issue": "Yes", 
                "time_frame": "blood and urine sampling during 0-48hr on SAD cohort, blood sampling during day 1, day 12-15 and urine sampling during day 1-2, day 14-15 on MAD cohort"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01870674"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "pharmacokinetics\n- SAD cohort: Cmax", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "SAD cohort: Blood and sampling during 0~48 hrs after administration"
            }, 
            {
                "description": "- SAD cohort: AUCt,", 
                "measure": "AUCt", 
                "safety_issue": "No", 
                "time_frame": "SAD cohort: Blood sampling during 0~48 hrs after administration"
            }, 
            {
                "description": "pharmacokinetics\n- SAD cohort: Aet", 
                "measure": "Aet", 
                "safety_issue": "No", 
                "time_frame": "SAD cohort: Urine sampling during 0~48 hrs after administration"
            }, 
            {
                "description": "pharmacokinetics\n- MAD cohort: Cmax", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "MAD cohort:Blood sampling during day1,12,13,14 ~16 after administration, urine sampling during day 1, day 14~ 15"
            }, 
            {
                "description": "pharmacokinetics\n- MAD cohort: AUCt", 
                "measure": "AUCt", 
                "safety_issue": "No", 
                "time_frame": "MAD cohort:Blood sampling during day1,12,13,14 ~16 after administration, urine sampling during day 1, day 14~ 15"
            }, 
            {
                "description": "pharmacokinetics\n- MAD cohort: Aet", 
                "measure": "Aet", 
                "safety_issue": "No", 
                "time_frame": "MAD cohort:urine sampling during day 1, day 14~ 15"
            }, 
            {
                "description": "pharmacodynamics\n- SAD: BSFs", 
                "measure": "BSFS", 
                "safety_issue": "No", 
                "time_frame": "SAD cohort: Day 1~7"
            }, 
            {
                "description": "pharmacodynamics\n- SAD: frequency of defecation", 
                "measure": "Frequency of defecation", 
                "safety_issue": "No", 
                "time_frame": "SAD cohort: Day 1~7"
            }, 
            {
                "description": "pharmacodynamics\n- MAD: BSFs", 
                "measure": "BSFS", 
                "safety_issue": "No", 
                "time_frame": "MAD cohort: Day 1~21"
            }, 
            {
                "description": "pharmacodynamics\n- MAD: frequency of defecation", 
                "measure": "Frequency of defecation", 
                "safety_issue": "No", 
                "time_frame": "MAD cohort: Day 1~21"
            }, 
            {
                "description": "pharmacodynamics\n- MAD cohort: Gastric emptying lag time", 
                "measure": "Gastic emptying lag time", 
                "safety_issue": "No", 
                "time_frame": "MAD cohort: Day 1~ 21"
            }, 
            {
                "description": "pharmacodynamics\n- MAD cohort: slope of fractional gastric emptying rate", 
                "measure": "Slope of fractional gastric emptying rate", 
                "safety_issue": "No", 
                "time_frame": "MAD cohort: Day 1 ~ 21"
            }, 
            {
                "description": "pharmacodynamics\n- MAD cohort: Colonic transit", 
                "measure": "Colonic transit", 
                "safety_issue": "No", 
                "time_frame": "MAD cohort: Day 1 ~ 21"
            }
        ], 
        "source": "Yuhan Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yuhan Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}